https://t.co/MYoTvX82lM pic.twitter.com/cqwF5j8pYp An estimated 2.7 percent of adults in the United States are immunocompromised, according to the CDC.
Specifically, these immunocompromised individuals are solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise, the US FDA said. "After a thorough review of the available data, the FDA determined that this small, vulnerable group may benefit from a third dose of the Pfizer-BioNTech or Moderna vaccines," FDA's acting commissioner said. “Today’s action allows doctors to boost immunity in certain immunocompromised individuals who need extra protection from COVID-19.